HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $89,552 | +4.3% | 2,344,305 | -1.5% | 0.90% | +10.6% |
| Q2 2023 | $85,831 | -6.4% | 2,379,589 | -0.9% | 0.81% | -8.3% |
| Q1 2023 | $91,736 | -22.8% | 2,402,115 | +15.0% | 0.89% | -26.3% |
| Q4 2022 | $118,856 | -99.9% | 2,088,856 | -5.2% | 1.20% | +25.4% |
| Q3 2022 | $87,108,000 | +20.5% | 2,203,042 | +34.1% | 0.96% | +23.2% |
| Q2 2022 | $72,309,000 | +9.6% | 1,643,388 | -0.6% | 0.78% | +32.7% |
| Q1 2022 | $65,956,000 | +5.2% | 1,653,859 | +6.1% | 0.59% | +12.2% |
| Q4 2021 | $62,673,000 | +2.8% | 1,558,644 | +4.0% | 0.52% | -3.9% |
| Q3 2021 | $60,970,000 | +26.3% | 1,498,769 | +41.0% | 0.54% | +29.8% |
| Q2 2021 | $48,280,000 | +9.1% | 1,063,194 | +0.2% | 0.42% | +2.9% |
| Q1 2021 | $44,243,000 | +23.0% | 1,061,230 | +26.0% | 0.41% | +7.9% |
| Q4 2020 | $35,972,000 | – | 842,255 | – | 0.38% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |